Tillotts Pharma AG To Acquire Global Rights for Entocort (budesonide) Outside The U.S. Under Agreement With AstraZeneca

Tillotts Pharma AG To Acquire Global Rights for Entocort (budesonide) Outside The U.S. Under Agreement With AstraZeneca
Rheinfelden, Switzerland based Tillotts Pharma AG ("Tillotts"), part of Japan's Zeria Group, has announced its entry into an agreement in which it will acquire global rights from London based AstraZeneca to market the drug Entocort (budesonide), excluding the U.S., where Entocort will continue to be marketed by AstraZeneca. Tillotts is under agreement to expand and diversify the company's portfolio by acquiring Entocort, an established, locally-acting glucocorticosteroid medicine, indicated for treatment inflammatory bowel diseases (IBD) from London, UK based AstraZeneca Entocort is available in two formulations: capsules and enema. Entocort capsules (3 mg) are a first-line locally acting glucocorticosteroid therapy indicated for the induction of remission of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon and maintenance of remission. Entocort Enema (0.02 mg/ml) is indicated for the induction and maintenance of clinical remission of distal ulcerative colitis in the rectum, sigmoid and descending colon. Entocort is currently available in over 40 countries, with total sales of approximately $53 million outside the US in 2014. A regulatory submission for Entocort in Japan is anticipated in the coming months. Tillotts says this transaction underscores its commitment to become a major European specialist in the field of gastroenterology, offering patients a wide range of treatments for gastrointestinal (GI) disorders while delivering value to shareholders A fast-growing speciality pharma company with over 200 emplo
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *